The paper appeared online July 17 in the British journal Diabetologia.
Research builds on previous discovery of gene TCF7L2’s link to type 2 diabetes
“This protein could be a central player in many different diseases and traits,” said study leader Struan F.A. Grant, PhD, a geneticist at The Children’s Hospital of Philadelphia and a faculty member of the University of Pennsylvania School of Medicine. The current finding builds on Grant’s 2006 discovery, now widely replicated, that a gene called TCF7L2 is strongly linked to type 2 diabetes.
Type 2 diabetes results either when the pancreas produces insufficient insulin or when the body’s insulin-processing cells develop resistance to insulin, causing blood sugar to rise to unhealthy levels.
Studying which genes transcription factor TCF7L2 regulates may suggest new drug development approaches
The TCF7L2 gene carries the code for a transcription factor–also called TCF7L2–a protein that binds to genes and regulates their activity. Exactly how this protein acts to affect diabetes is still unknown. However, Grant noted that there is great scientific interest in identifying which genes the transcription factor regulates. “It may be more feasible to develop drugs aimed at proteins encoded by specific gene classes regulated by TCF7L2 that are more amenable to targeted interventions, rather than aiming at a more ubiquitous transcription factor,” he said.
Because variants in the TCF7L2 gene are also associated with risk for different cancers, including colorectal cancers, there was even greater reason to learn details of its biological activity. “Our goal,” said Grant, “was to simply uncover the repertoire of genes that this transcription factor controls.”
ChIP-sequencing shows TCF7L2 protein binding sites at many gene locations with known disease links
Collaborating with investigators at the University of Pennsylvania, Grant used a technique called ChIP-sequencing, which locates and compiles the DNA sequences of genes to which proteins bind. “This uses the latest-generation sequencing technology that has only recently become feasible, allowing investigators to rapidly sequence at the scale of whole genomes,” said Grant. In human cell lines, this ChIP approach identified and mapped DNA sequences of TCF7L2 binding sites at over 1,000 gene locations.
“What was unexpected and striking about our results was that this transcription factor binds to a large number of gene locations already implicated in disease from previous GWAS research,” said Grant. In the last five years, GWAS, or genome-wide association studies, have proven to be highly successful in scouring the genome to locate gene sites associated with particular diseases.
Findings and next steps
“We found an over-representation of genes associated with metabolic disorders, such as diabetes, but also with cardiovascular disorders, such as coronary artery disease and atherosclerosis,” Grant added. “We expect to follow up these initial observations with functional research to investigate how these genes operate in these diseases, and whether these genes may become candidates for better therapies. For now, our work suggests that this transcription factor may be a central node in a network of genes associated not only with type 2 diabetes, but also exerting its influence much further in contributing to other genetic diseases.”
Funding for the study
A grant from the Ethel Brown Foerderer Fund for Excellence from The Children’s Hospital of Philadelphia supported this study, with added support from the National Institute of Diabetes, Digestive and Kidney Disorders, the Penn Center for Musculoskeletal Disorders, and the University of Pennsylvania Diabetes and Endocrinology Research Center. Grant’s co-authors were Klaus H. Kaestner, PhD, Jonathan Schug, PhD, and Mingyao Li, PhD, of the University of Pennsylvania; and Jianhua Zhao, PhD, of Children’s Hospital.
“Disease-associated loci are significantly over-represented among genes bound by transcription factor 7-like 2 (TCF7L2) in vivo,” Diabetologia, published online July 17, 2010. doi: 10.1007/s00125-010-1852-3
Read the abstract
Contact: John Ascenzi, Department of Public Relations, 267-426-6055